Online Consultation For Papillary Thyroid Cancer Treatment Doctors in Spain

Dr. Raimon Mirabell is a specialized Radiation Oncologist in Spain. And one of the most sought after medical specialists in Barcelona, Spain. The doctor has over 35 Years of experience and is associated with Hospital Quirnsalud Barcelona.

Association and Memberships Dr. Raimon Mirabell is part of:

• Member of the Group for Radiotherapy of Brain Tumors of the EORTC (European Organization for Research and Treatment of Cancer) and President of the Swiss Proton Users Group.

Qualifications :

• 1971- 1977 Medicina Studies at the Autonomous University of Barcelona.
• 1979-1984 Residence in Radiotherapy at the Hospital de Sant Pau,Barcelona.

Hospital Address :

Hospital Quir

Medical Expertise of Dr. Raimon Mirabell

• Dr. Mirabell majorly specializes in treating Prostate Cancer
• Frequent Radiation procedure provided by the specialist are Radiotherapy, Transarterial Chemoembolization - TACE, and IMRT
• Dr Miralbell is a renowned, board-certified Radio-oncologist in Spain
• Dr Mirabell has been trained internationally in prestigious institutions such as Radiation Medicine Department, Harvard Cyclotron, City of Hope National Medical Center in Duarte-California,
• Dr. Mirabell is the member of the Group for Radiotherapy of Brain Tumors of the EORTC (European Organization for Research and Treatment of Cancer) and President of the Swiss Proton Users Group.
• He has contributed to textbooks and monographs as a chapter author. He has over 170 scientific articles in peer-reviewed journals around the world.
• He has also given presentations at conferences as well.

Dr. Joan Carles Galceran is a specialized Medical Oncologist in Spain. And one of the most sought after medical specialists in Barcelona, Spain. The doctor has over 25 Years of experience and is associated with Centro Medico Teknon.

Association and Memberships Dr. Joan Carles Galceran is part of:

• Member of the American Association of Clinical Oncology (ASCO)
• European Association for Medical Oncology (ESMO).
• Spanish Society of Medical Oncology (SEOM).

Certifications :

• He completed his studies by obtaining the European Certificate in Medical Oncology in Vienna in November 1996.

Qualifications :

• Dr. Joan Carles Galceran graduated in Medicine and Surgery at the University of Barcelona in 1987.
• Ph.D., with cum laude, in 1992 from the Autonomous University of Barcelona.

Hospital Address :

Centro M

What is the medical expertise of Dr Joan Carles Galceran?

• With over 25 years of experience, Dr Joan Carles Galceran is a leading oncologist specializing in sarcoma, kidney cancer, bladder cancer, and prostate cancer treatment. His expertise includes immunotherapy and chemotherapy.
• Dr Carles is associated with noteworthy organizations such as the European Society for Medical Oncology(ESMO), the Spanish Society of Head and Neck Tumors(CTT), the Spanish Sarcoma Research Group(GEIS), the American Society of Clinical Oncology(ASCO) and the Spanish Association of Medical Oncology(SEOM). He is the Secretary and Co-founder of the Spanish Oncology Genitourinary Group(SOGUG).
• In 1996, he obtained the European Certificate in Medical Oncology in Vienna.
• Dr Carles has more than 70 peer-reviewed papers to his credit. Some of his publications include:
  1. Carles J, Alonso-Gordoa T, Mellado B, Méndez-Vidal MJ, et al. Radium-223 for patients with metastatic castration-resistant prostate cancer with asymptomatic bone metastases progressing on first-line abiraterone acetate or enzalutamide: A single-arm phase II trial. Eur J Cancer. 2022 Sep;173:317-326.
  2. Suarez C, Marmolejo D, Valdivia A, Morales-Barrera R, Gonzalez M, Mateo J, Semidey ME, Lorente D, Trilla E, Carles J. Update in collecting duct carcinoma: Current aspects of the clinical and molecular characterization of an orphan disease. Front Oncol. 2022 Oct 4;12:970199.
  3. Agarwal N, Azad A, Carles J, et al. A phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer. Future Oncol. 2022 Mar;18(10):1185-1198.